We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Qiagen Acquires Exclusive Licence for Key PI3K gene
News

Qiagen Acquires Exclusive Licence for Key PI3K gene

Qiagen Acquires Exclusive Licence for Key PI3K gene
News

Qiagen Acquires Exclusive Licence for Key PI3K gene

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Qiagen Acquires Exclusive Licence for Key PI3K gene"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Qiagen today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.
Research has shown that variation in the PI3K gene could be a key biomarker for use as a companion diagnostic with certain cancer treatments. The studies suggest that mutations in the PI3K oncogene are predictive for the success of certain treatments of patients suffering from lung, breast, colorectal and other cancers. Qiagen has an active PI3K assay development and partnering program with pharmaceutical companies to develop and market tests for new cancer drug candidates.

The patent for PI3K mutations in human cancers was initially filed by researchers at Johns Hopkins who assessed the biomarker during their evaluation of tyrosine kinase inhibitors targeting the EGFR (Epidermal Growth Factor Receptor) pathway. Various EGFR inhibiting drugs have shown to be not effective in cancer patients with mutations in genes of the EGFR pathway (EGFR, K-RAS, B-RAF etc.). QIAGEN already markets several tests determining the mutation status in oncogenes. This portfolio includes tests for mutations of K-RAS and B-RAF, which are indicative for metastatic colorectal, lung and other cancers. The K-RAS test is CE-marked for companion diagnostic use with EGFR inhibitors Vectibix® and Erbitux® and is expected to be submitted for FDA approval shortly.

"This license agreement is another step forward for QIAGEN and for the use of novel therapeutics that rely on the widespread availability of the required PI3K companion diagnostic test", said Peer M. Schatz, CEO of QIAGEN. "We are looking forward to developing drug-diagnostic combinations together with pharmaceutical partners for the selection of the right patient for the right medicine. This concept allows cancer patients to receive better treatments and can support healthcare systems to provide the most useful therapies in cost effective ways."

Advertisement